Associations between pre-existing comorbidities and in-hospital cardiovascular events and mortality among COVID-19 patients in Bangladesh: a secondary analysis of a prospective cohort study
=============================================================================================================================================================================================

* Farzana Islam
* Kazi Fayzus Salahin
* Abdul Wadud Chowdhury
* Md. Robed Amin
* Abdur Rahim
* Shahin Akter
* Shamim Talukder
* Quazi Monirul Islam
* Tippawan Liabsuetrakul

## Abstract

**Objective** To identify the associations of in-hospital cardiovascular events and mortality with pre-existing comorbidities and cardiovascular disease (CVD) risk factors among COVID-19 patients in Bangladesh without vaccine availability.

**Design** A secondary analysis of a prospective multicountry study.

**Setting** Three COVID-19-designated hospitals in Bangladesh.

**Participants** Adult patients aged ≥18 years with PCR-positive COVID-19 admitted between 10 October 2020 and 31 July 2021 at participating hospitals.

**Outcome measures** In-hospital cardiovascular events and mortality.

**Main exposures** Pre-existing comorbidities and cardiovascular risk factors.

**Results** In 897 COVID-19 patients, 18.7% developed cardiovascular events and 12.6% died. After adjusting for clinical information and treatment, patients with two comorbidities (excluding CVD risk factors) were significantly associated with cardiovascular events (adjusted (adj.) OR 2.47, 95% CI 1.24 to 4.90). Patients with a higher heart rate at admission (adj. OR 1.03, 95% CI 1.01 to 1.04) and those who were receiving intravenous fluids (adj. OR 2.13, 95% CI 1.23 to 3.70) or antibiotics (adj. OR 4.54, 95% CI 1.47 to 14.01) had significantly higher odds of cardiovascular events. The odds of cardiovascular events were lower in those receiving antiviral medications (adj. OR 0.31, 95% CI 0.18 to 0.53). There were no interactions between comorbidities and other covariates in the models. Comorbidities and cardiovascular risk factors were not significantly associated with 30-day mortality in the Cox regression models after adjusting with clinical information and treatment. The mortality within 30 days of admission was significantly higher in patients receiving corticosteroids (adj. HR 2.82, 95% CI 1.48 to 5.38) and lower in those receiving antiviral treatment (adj. HR 0.53, 95% CI 0.34 to 0.81). Those having cardiovascular events significantly increased mortality hazard.

**Conclusions** Clinical factors and treatment affected in-hospital cardiovascular events, which subsequently increased the risk of mortality within 30 days for COVID-19 patients. COVID-19 patients regardless of CVD risk factors and comorbidities require close monitoring for cardiovascular events.

*   COVID-19
*   mortality
*   cardiac epidemiology
*   health services
*   public health
*   cardiovascular disease

### STRENGTHS AND LIMITATIONS OF THIS STUDY

*   In-hospital cardiovascular events and mortality among COVID-19 patients with large sample sizes were studied in Bangladesh, South Asia.

*   Patient cardiovascular risk factors and comorbidities were examined accompanied by clinical information and treatment on admission.

*   Our study provides robust evidence from a secondary analysis of a prospective study.

*   Data on cardiovascular events and mortality among prevaccine COVID-19 patients were presented.

*   Laboratory parameters were not included in this secondary analysis.

## Introduction

The global population has been greatly affected by COVID-19, which was declared as a global pandemic by WHO in 2020.1 The first case of COVID-19 in Bangladesh was detected on 8 March 2020 and up to 12 August 2023, >2 million cases were confirmed, resulting in 29 446 deaths.2 Although most of the COVID-19 patients in Bangladesh had only mild symptoms, there were still significant hospitalisations and adverse outcomes.3 A systematic review, assessing the mortality of COVID-19 patients in the publications searched up to April 2020, primarily from China, indicated an increased likelihood of in-hospital mortality among COVID-19 patients after adjusting for age; however, no significant associations were observed between gender or smoking status and in-hospital mortality.4 Another systematic review up to June 2020 also mainly from China concluded that age, gender, smoking and pre-existing conditions such as diabetes, hypertension, cardiovascular diseases, kidney diseases and respiratory diseases contributed to a higher risk of mortality among COVID-19 patients.5 These two systematic reviews shed light on the inconsistencies in the reported magnitude of in-hospital mortality concerning comorbidities and cardiovascular risk factors. It is important to note that most of the studies included in these systematic reviews were conducted in China, where population characteristics and the impact of comorbidities might differ from those in South Asian countries like Bangladesh.

COVID-19 is caused by the SARS-CoV-2 virus which consists of four structural proteins, the spike (S) protein, the nucleocapsid (N) protein, the membrane (M) protein and the envelope (E) protein, and 16 non-structural proteins. The S protein has S1 and S2 subunits which can interact directly with ACE 2, predominantly expressed in the nasal mucous membranes, lung, heart, liver and brain resulting in cell invasion and direct organ damage.6 Elevations of cardiac biomarkers indicating cardiac injury or cardiovascular disease can be affected by COVID-19.7 Clinical outcomes of SARS-CoV-2 infection in terms of hospitalisation, morbidity and mortality vary depending on the variant of concern, risk factors, treatment and vaccination status.6 7 Previous studies have identified associations between adverse outcomes, specifically cardiovascular diseases (CVDs), in COVID-19 patients and cardiovascular risk factors such as older age, male sex, overweight, smoking, hypertension and diabetes.8–14 CVDs are highly prevalent in high-income Asian and Western countries due to population growth and ageing.15

In Bangladesh, after December 2020, Wuhan-like variants were consecutively replaced by the Alpha, Gamma, Eta, Beta, Delta and Omicron variants, respectively.16 17 The infection rates and case fatality rates varied along with the dynamics of the variants throughout the period. The Delta and Beta variants were among the COVID-19 variants associated with higher infection rates in 2021.18 A nationwide immunisation campaign against COVID‐19 was launched among anyone aged 40 years or older in February 2021 and those aged 18 years or older in 10 August 202119; however, the coverage was still low, particularly among the elderly who were the most vulnerable.20 In recent years, Bangladesh has been facing disease transition due to rapid urbanisation and socio-economic and lifestyle changes21 22 and CVD risk factors are now the highest among South Asian countries.23 Furthermore, there is a lack of research investigating the relationship between common clinical presentations of COVID-19 patients and the impact of in-hospital management on patient outcomes.

The protocol of a prospective multicountry study, the ‘World Health Federation (WHF) COVID-19 and Cardiovascular Disease Survey’ was published in April 202124 and the main results of the WHF global study on the description of cardiovascular risk factors and clinical outcomes among hospitalised COVID-19 patients across diverse populations was published in 2022.25 This study involved 23 countries including Bangladesh, which collected data on COVID-19 patients from October 2020 to July 2021 exclusively from patients who had not received a COVID-19 vaccine in Bangladesh, a period during which the Alpha, Beta and Delta variants were reported in the country. The secondary analysis of this study aimed to identify in-hospital cardiovascular events and mortality among COVID-19 patients in Bangladesh and to assess the effects of pre-existing comorbidities and cardiovascular risk factors on in-hospital cardiovascular events and mortality among COVID-19 patients. The information from this analysis can be useful as guidance concerning the clinical benefits and public health implications in the context of various COVID-19 variants, where vaccinations were not yet available.

## Methods

### Design and study participants

This secondary analysis used the data of adult patients aged ≥18 years with PCR-positive COVID-19 admitted between 10 October 2020 and 31 July 2021 in three COVID-19-designated hospitals in Bangladesh, as per the original study. The original study collected the variables as follows: demographic characteristics, pre-existing medical conditions, clinical condition and treatment during hospital admission and clinical outcomes such as death, major adverse cardiovascular events, renal failure, neurological events or pulmonary outcomes at the time of hospital discharge or at the 30-day follow-up after initial admission if already discharged.24

### Variables

The main outcome measures of this study were in-hospital cardiovascular events and mortality. In-hospital cardiovascular events included shock, myocarditis, myocardial infarction, pericarditis, acute heart failure, endocarditis, atrial fibrillation, cardiac arrest, heart blocks and ischaemic stroke, which were included in the composite outcome of major adverse cardiac events used in previous studies26 27 and the study protocol of a main survey.24 Death was recorded for up to 30 days after the initial admission of the COVID-19 patients. Patients who were discharged before 30 days were called to check their status by phone. The recorded causes of death were sudden cardiac death or death due to myocardial infarction, heart failure, stroke, pulmonary embolus, respiratory failure or other causes.

The exposure variables in this study encompassed CVD risk factors and comorbidities. Specifically, the CVD risk factors included age, gender, education level, body mass index (BMI) and smoking status. Education, BMI and smoking were selected as CVD risk factors based on a multicountry community-based prospective cohort study in South Asia.28 Overweight and obesity were defined as a BMI over 25 or 30, respectively. BMI is an anthropometric index of weight and height calculated by dividing a person’s weight by the square of their height (kilograms/metre squared). Comorbidities included both pre-existing cardiovascular and non-cardiovascular conditions prior to admission as reviewed from hospital records. Cardiovascular comorbidities were coronary artery disease, stroke, peripheral vascular disease, atrial fibrillation, heart failure, cardiomyopathies, rheumatic heart disease, Chagas disease, congenital heart disease, valvular disease and hypertension. Non-cardiovascular comorbidities were diabetes, chronic pulmonary disease, chronic kidney disease, asthma, previous organ transplant, tuberculosis, cancer on chemotherapy, HIV, chronic immunosuppression and renal replacement therapy. Comorbidities were then classified into four categories: none, one, two and more than two pre-existing diseases.

The clinical information recorded at admission included temperature, heart rate, SpO2 level, systolic blood pressure and diastolic blood pressure. The treatments on admission were intravenous fluids, antiviral treatment, corticosteroids, antibiotics, ACE inhibitors, angiotensin II receptor blockers and antithrombotic/anticoagulant agents.

### Statistical analysis

We used descriptive statistics for categorical variables in counts and percentages, while continuous variables were expressed as means (SD) or medians with IQR. Differences in categorical outcomes between patients who had and those who did not have in-hospital cardiovascular events were tested using the χ2 test. To assess the impact of pre-existing comorbidities—particularly multicomorbidities compared with no comorbidity—and cardiovascular risk factors on in-hospital cardiovascular events among the COVID-19 patients, we used a stepwise binary logistic model to calculate adjusted ORs (adj. ORs) and 95% CIs. Initially, we examined the exposure variables, specifically cardiovascular risk factors, and subsequently considered the clinical information and treatment received on admission. The interactions between comorbidities and other covariates in the models were tested for independence between covariates. The best fitting dataset in the individual model of clinical information and treatment received on admission with comorbidities was selected based on the lowest Akaike information criterion values.

We generated Kaplan-Meier cumulative incidence plots to visualise the survival data comparing individuals with the comorbidities, as well as those who experienced cardiovascular events versus those who did not. The significance of these differences was assessed using the log-rank test. To analyse mortality rates, we estimated HRs using a Cox proportional hazards model. The time-to-event was measured in days from hospital admission to either in-hospital death or death within 30 days of follow-up if the patient had already been discharged. Two Cox proportional hazards models were employed in the analysis. Model 1 examined the effects of comorbidities and CVD risk factors and model 2 included the variables from model 1 as well as clinical information and treatment administered on admission. The assumptions of proportionality of hazard were verified for the application of the Cox regression model using individual and global Schoenfeld tests. For any predictor that violated the proportional hazards assumption, we stratified the model by that predictor, meaning it was no longer directly tested or presented in the final model. We then repeated the Schoenfeld tests to ensure that the assumption was satisfied within the stratified model. Statistical significance was defined as p<0.05. The statistical analyses were performed using R V.4.2.3 (The R Foundation for Statistical Computing Platform, 2022).

### Patient and public involvement

The study patients or the public were not involved in the design, conduct, reporting or dissemination plans of our research.

## Results

During the study period, 897 adult patients with COVID-19 were admitted to the study hospitals. A description of the cardiovascular risk factors for the study’s COVID-19 patients is provided in table 1. Almost half of the patients were aged between 46 and 65 years and 23.5% of patients were elderly aged >65 years. Male patients slightly outnumbered females. Two-thirds had an education of at least secondary school and had never smoked and almost half were overweight or obese.

View this table:
[Table 1](http://bmjopen.bmj.com/content/14/8/e083982/T1)

Table 1 
Description of cardiovascular risk factors for the study’s COVID-19 patients

Table 2 describes the existing cardiovascular and non-cardiovascular comorbidities for the study’s COVID-19 patients at admission and any cardiovascular events occurring at 30-day of follow-up. Among 897 patients, 276 (30.8%) had no comorbidities and 614 (68.4%) had at least one comorbidity. Of those with comorbidities, 248 (40.4%) had 1, 250 (40.7%) had 2 and 116 (18.9%) had more than 2 comorbidities. Cardiovascular comorbidities were found in 490 patients (54.6%). Among these, hypertension was the most common (n=481, 98.2%), followed by coronary artery disease (n=51, 10.4%), congenital heart disease (n=25, 5.1%) and stroke (n=16, 3.3%). Non-cardiovascular comorbidities were found in 455 patients (50.7%). Among these, diabetes was the most common (n=394, 86.6%), followed by asthma (n=70, 15.4%) and chronic kidney disease (n=62, 13.6%). Cardiovascular events were diagnosed in 167 patients (18.7%). Myocarditis, pericarditis and endocarditis were all found in <l% of the patients (online supplemental table 1). Of all 897 patients, 101 died during admission (11.3%) and an additional 12 died during the 30-day follow-up period (1.5%), resulting in a total of 113 deaths (12.6%). Death was significantly more common in those with cardiovascular events (53/167, 31.7%) than those without events (59/726, 8.1%) (p<0.001) (online supplemental table 2).

### Supplementary data

[[bmjopen-2024-083982supp001.pdf]](pending:yes)

View this table:
[Table 2](http://bmjopen.bmj.com/content/14/8/e083982/T2)

Table 2 
Description of existing cardiovascular and non-cardiovascular comorbidities for the study’s COVID-19 patients at admission and any cardiovascular events occurring at 30-day follow-up

Table 3 presents the associations between pre-existing comorbidities, cardiovascular risk factors and in-hospital cardiovascular events, adjusted for clinical information and management, in the study’s COVID-19 patients. In univariate analysis, patients with two or more comorbidities had higher odds of experiencing in-hospital cardiovascular events compared with COVID-19 patients with no comorbidities. Those who had more than two diseases in the model 1 after adjusting for cardiovascular risk factors and those had two diseases in the model 2 after adjusting for clinical information and treatments on admission showed significantly higher odds of having cardiovascular events. In the model 1, those having education lower than college/university had increased odds of in-hospital cardiovascular events, while former or unknown smoker, or overweight had lower odds. After adjusting for clinical information and treatments on admission as seen in model 2, CVD risk factors were not significantly associated with cardiovascular events. Patients with a higher heart rate at admission (adj. OR 1.03, 95% CI 1.01 to 1.04) and those who were receiving intravenous fluids (adj. OR 2.13, 95% CI 1.23 to 3.70) or antibiotics (adj. OR 4.54, 95% CI 1.47 to 14.01) had significantly higher odds of cardiovascular events. The odds of cardiovascular events were lower in those receiving antiviral medications (adj. OR 0.31, 95% CI 0.18 to 0.53). No interactions between comorbidities and other covariates in the model 1 and model 2 were found.

View this table:
[Table 3](http://bmjopen.bmj.com/content/14/8/e083982/T3)

Table 3 
Effects of pre-existing comorbidities and cardiovascular risk factors, adjusted for clinical information and treatment on admission, on in-hospital cardiovascular events

The factors associated with 30-day mortality in the Cox regression model are shown in table 4. Based on the assumption of proportional hazard, the comorbidities and cardiovascular risk factors were not significantly associated with the mortality (model 1). In model 2, those who received antiviral treatment had a lower hazard of mortality compared with those who did not receive antiviral treatment (adj. HR 0.53, 95% CI 0.34 to 0.81). Almost triple HRs were found in those treated with corticosteroids (adj. HR 2.82, 95% CI 1.48 to 5.38). Mortality increased in patients with cardiovascular events (HR 4.10, 95% CI 2.82 to 5.96); however, this variable was not included in the multivariate Cox regression model due to a violation of assumptions. The probabilities of death in COVID-19 patients within 30-day follow-up stratified by comorbidities and the occurrence of cardiovascular events are presented by the Kaplan-Meier survival curves (figure 1). Four curves of the comorbidities were not statistically significantly different as shown in figure 1A (p=0.450). The probability of death was higher in COVID-19 patients with cardiovascular events compared with those without cardiovascular events (p<0.001) as shown in figure 1B.

![Figure 1](http://bmjopen.bmj.com/http://bmjopenuat.stage.highwire.org/content/bmjopen/14/8/e083982/F1.medium.gif)

[Figure 1](http://bmjopen.bmj.com/content/14/8/e083982/F1)

Figure 1 
Kaplan-Meier survival curves in COVID-19 patients without and different number of comorbidities, n=879 (A) and those with or without cardiovascular events, n=889 (B).

View this table:
[Table 4](http://bmjopen.bmj.com/content/14/8/e083982/T4)

Table 4 
Factors associated with 30-day mortality in a Cox regression model

## Discussion

Two-thirds of the COVID-19 patients admitted to the study hospitals during the study period had pre-existing comorbidities, with approximately half having either hypertension or diabetes. Approximately 1 out of 4 patients were aged over 65 years and almost half were overweight or obese. Approximately 19% were diagnosed with cardiovascular events during admission and 11% died during admission and an additional 1.5% died after discharge within 30 days of follow-up. Pre-existing comorbidities and CVD risk factors were associated with in-hospital cardiovascular events. However, after adjusting for clinical information and medications at admission, only the presence of at least two comorbidities remained significant. A significantly higher death rate was found in the COVID-19 patients with cardiovascular events than those without such events. The probability of death within 30 days in the COVID-19 patients aged over 65 years was higher than those aged <26 years in univariate analysis, but the difference was not significant after adjusting for clinical information and medications on admission; there was no evidence of an association with comorbidities.

A Cochrane review found that cardiovascular comorbidities and complications were common in hospitalised COVID-19 patients; however, almost half of their reviewed studies originated from China and the majority of studies were retrospective.29 In early 2020, COVID-19 patients with cardiovascular or non-cardiovascular comorbidities had higher chances of severe outcomes.30 The incidence of cardiovascular events in our study (19%) falls within the range reported in another systematic review, which reported 8.5% in survivors and 21.6% in non-survivors.31 Mortality in hospitalised patients from the systematic review and individual studies varied from 12.0% to 31.8%.4 32–34 The higher mortality rates reported in those previous studies compared with our study may be due to the fact that the majority of hospitalised patients in those studies were older and had more underlying diseases.

For cardiovascular risk factors, our study identified age as a major independent contributor to cardiovascular events, with patients aged over 46 years having a threefold higher risk compared with those aged 25 years or younger. This finding aligns with previous research, indicating a consistent association between advancing age and increased risk of major cardiovascular events and mortality.8 35 We also found a borderline significant difference in in-hospital cardiovascular events between females and males after adjusting for cardiovascular risk factors. These findings may reflect the complexity of other clinical and biological factors in males and females in our study. The previous studies showed that clinical features play a role in determining the severity of a disease and influencing death rates.36 37 The effects of gender on cardiovascular events and death remain uncertain, as previous studies conducted in the USA, the Philippines and China have reported varying findings. These range from no significant differences in death rates by gender to higher mortality rates in males, juxtaposed with higher incidences of CVDs in females.38–40

The significance of education, smoking status or BMI group in our study disappeared after adjusting for clinical information and treatment on admission in the models predicting cardiovascular events and mortality. This may be explained by the finding that the clinical features and medical treatment on admission were more strongly associated with cardiovascular events and mortality than the cardiovascular risk factors. This is consistent with a prior study demonstrating a prediction model of major adverse cardiovascular events in COVID-19 patients.8 A systematic review and meta‐analysis also found an association between CVDs and laboratory results with severe outcomes of COVID-19 patients; however, the certainty of the evidence in this review was limited due to the small number of prospective studies included.5 We did not find any effects of cardiovascular-related medications on death, similar to a previous study which examined the associations of renin-angiotensin-aldosterone system inhibitors, calcium channel blockers, diuretics and beta-blockers on the patients’ prognoses.32

Our study provides robust evidence from a secondary analysis of a prospective study on COVID-19 in-hospital cardiovascular events and mortality, which can guide future healthcare preparedness for care of major adverse cardiovascular events in future pandemic-like COVID-19 situations, particularly in low- and middle-income countries, like Bangladesh. The cardiovascular events examined in our study were similar to the cardiovascular outcomes recorded in the American Heart Association COVID-19 Cardiovascular Disease Registry.41 A recent systematic review published in 2023 supported our findings in univariate analysis that pre-existing CVDs were associated with acute cardiovascular complications.42 Although comorbidities and other cardiovascular risk factors were shown to be associated with cardiovascular events and mortality in COVID-19 patients in previous studies, their effects varied depending on various demographic characteristics of the patients, study settings and designs, analytical methods, treatments on admission and other clinical factors. In our study, the significance of having at least two pre-existing comorbidities on cardiovascular events, but not on mortality, was consistent with the findings from a population-based study in Italy. That study also found that a higher number of comorbidities increased the risks of severe COVID-19-related hospitalisation.43 Cardiovascular events and mortality in our study’s multivariate Cox regression models was similar to the findings from a study in Greece conducted during the dominance of the Delta and Omicron variants.44

Clinical presentation indicating cardiovascular responses such as heart rate, blood pressure and oxygen saturation, and treatment on admission with intravenous fluids, antiviral and antibiotic treatments, and any cardiovascular events found in our study are important for providing proper monitoring and medical care. A high heart rate at admission increased the odds of detection of cardiovascular events after adjusting for comorbidities, cardiovascular risk factors and medications on admission. This finding is consistent with a study conducted in Brazil, which reported higher heart rates in the COVID-19 patients with pre-existing CVDs who had endothelial dysfunction.45 The use of antiviral medications in our COVID-19 patients significantly reduced the rate of cardiovascular events. This finding is supported by a multicentre study in Taiwan, which found antiviral agents were associated with fewer adverse cardiovascular outcomes.46 We could not find any studies which directly supported the mechanism of intravenous fluid increasing the odds of the occurrence of cardiovascular events after admission but a lower risk of mortality in COVID-19 patients; however, it may be related to fluid volume and pressure overloads resulting in cardiac stress and then cardiovascular events.47 Likewise, the use of antibiotics may be coincidently associated with secondary bacterial infections, which could result in a higher incidence of cardiovascular events.

Our study found that managing COVID-19 patients with corticosteroids was associated with higher mortality, which was different from the findings of a study from Italy which collected data until May 2020 and found that corticosteroids had no effect on hospital mortality in patients with COVID-19.48 In contrast, a multicentre study conducted in 36 hospitals in France during January–May 2020 found that dexamethasone had significant association with reducing mortality in patients with respiratory support, defined as the use of oxygen or mechanical ventilation, but not in those without respiratory support.49 Likewise, the trial in the UK included COVID-19 patients admitted from March to June 2020, with 60% of patients receiving oxygen therapy and 16% receiving mechanical ventilation. The trial showed that the use of dexamethasone for up to 10 days in patients receiving mechanical ventilation or oxygen reduced 28-day mortality.50 In addition, the use of corticosteroids for treatment of myocarditis associated with COVID-19 was shown to improve outcomes in a systematic review.48 The different findings of our study compared with previous studies may be explained through several factors: different patient characteristics, with our study having less severe cases as only four patients required mechanical intubation; different study periods, which were influenced by various variants of SARS-CoV-2, the availability of vaccines, the incidence of myocarditis; and different clinical managements, including the use of corticosteroids or respiratory support.

Some findings of our study were different from previous studies due to the rapidly changing nature of the virus, demographical variations of the affected populations, diverse health systems or healthcare management of the COVID-19 patients and a lack of quality research methodology due to the urgent need for COVID-19 research to combat the pandemic and save lives. The sample size in this study was larger than another study conducted in different hospitals in Bangladesh.51 Even though the degrees of SARS-CoV-2 virulence and its clinical outcomes changed over the years of the pandemic, the lessons learnt in terms of optimal treatments of potential CVDs, clinicians’ safety, healthcare providers’ capacity and prompt adoption of relevant health policies should be taken into account,52 considering each patient’s cardiovascular risk factors and comorbidities.

The study had some limitations. First, the data analysed were limited from October 2020 to July 2021 when Bangladesh had been going through the second and third waves of COVID-19 infections and imposed stricter measures to control the devastating situation. Second, some data of the sociodemographic characteristics of the patients were not reported due to restrictions in the COVID-19 dedicated hospitals and the characteristics were collected from the patient history sheets. Third, at the time of data collection for this study, the COVID-19 vaccine was not yet available. Among the patients included in our study, cardiovascular events and death were reported in 18.7% and 12.6% of cases, respectively. Subsequent studies on COVID-19 patients have since shown a decrease in such events among vaccinated individuals compared with those who were not vaccinated.53 54 Fourth, the majority of pre-existing comorbidities in COVID-19 patients in this study were hypertension and diabetes mellitus, which predominated the results of two studied outcomes. Fifth, the laboratory parameters were not included in this secondary analysis as those were analysed and published in the main findings of original study. Finally, the severity of COVID-19 infection related to mortality depended on variants present during the study periods, which may not be generalisable to the current situation.

## Conclusions

Our findings support the hypothesis that comorbidities in COVID-19 patients have an adverse impact on the occurrence of cardiovascular events and an association with increased mortality. Close attention to the clinical information of patients diagnosed with COVID-19 on hospital admission is crucial and proper management with respect to the administration of intravenous fluids and antivirals, antibiotics and corticosteroids as well as monitoring for the presence of cardiovascular events should be standard procedure for such patients. Even though the serious health consequences of COVID-19 nowadays may be ameliorated by changing viral virulence and available treatments, the results of this analysis can be a lesson learnt concerning COVID-19 regarding the effects of comorbidities on cardiovascular events and mortality to assist with well-prepared health system responses and clinical care services for future pandemic-like COVID-19 situations.

## Data availability statement

Data are available on reasonable request. The datasets used and/or analysed during the current study are available from the organisation of the first author on reasonable request.

## Ethics statements

### Patient consent for publication

Not applicable.

### Ethics approval

This study of secondary analysis was approved by the Human Research Ethics Committee, Faculty of Medicine, Prince of Songkla University (REC.66-055-18-1) and the original study was approved the Bangladesh Medical Research Association (BMRC). Participants gave informed consent to participate in the study before taking part in original study.

## Acknowledgments

We would like to express our appreciation to the World Health Federation (WHF) Global Study COVID-19 and Cardiovascular Disease Survey funded by the WHF, and an unconditional research grant by Sanofi and Pfizer for the approval to use the Bangladesh data for this secondary analysis. We also thank Dave Patterson, International Affairs Office, Faculty of Medicine, Prince of Songkla University, for language editing.

## Footnotes

*   FI and TL contributed equally.

*   Contributors All the authors of this article contributed significantly to the conception and methodology of the study. FI, KFS, TL worked on data analysis and interpretation of the data. FI and TL drafted the first version of manuscript and then KFS, AWC, MRA, AR, SA, ST, QMI critically commented the work. TL was responsible in revising the manuscript with the involvement of intellectual input of all authors. All authors reviewed and approved the final version to be published and were accountable for all aspects related to the accuracy or integrity of any part of the work. TL is the guarantor of this secondary analysis and accepts full responsibility for the finished work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

*   Funding This secondary analysis was partially financially supported by Prince of Songkla University and the Ministry of Higher Education, Science, Research, and Innovation under the Reinventing University Project (Grant Number REV65020) through a PSU International Research Fellowship 2022.

*   Disclaimer The funding agencies were not involved in the study design, conduct, analysis or reporting of the results or manuscript preparation.

*   Competing interests None declared.

*   Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

*   Provenance and peer review Not commissioned; externally peer reviewed.

*   Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

[http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/).

## References

1.  Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020;91:157–60. [doi:10.23750/abm.v91i1.9397](http://dx.doi.org/10.23750/abm.v91i1.9397)
    
    [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.23750/abm.v91i1.9397&link_type=DOI) 
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=32191675&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

2.  Directorate, General of Health Services. COVID-19 dynamic dashboard for Bangladesh. Coronavirus COVID-19 dashboard, 2020, Available: [http://dashboard.dghs.gov.bd/webportal/pages/covid19.php](http://dashboard.dghs.gov.bd/webportal/pages/covid19.php)
    
    

3.  Bhuyan MA, Al Mahtab M, Ashab E, et al. Treatment of COVID-19 patients at a medical college hospital in Bangladesh. Eur J Hepatogastroenterol 2020;10:27–30. [doi:10.5005/jp-journals-10018-1317](http://dx.doi.org/10.5005/jp-journals-10018-1317)
    
    

4.  Silverio A, Di Maio M, Citro R, et al. Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients. BMC Cardiovasc Disord 2021;21:23. [doi:10.1186/s12872-020-01816-3](http://dx.doi.org/10.1186/s12872-020-01816-3)
    
    

5.  Zhu Z, Wang M, Lin W, et al. Cardiac biomarkers, cardiac injury, and comorbidities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Immun Inflamm Dis 2021;9:1071–100. [doi:10.1002/iid3.471](http://dx.doi.org/10.1002/iid3.471)
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=34405950&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

6.  Szpulak A, Garlak U, Ćwirko H, et al. SARS-CoV-2 and its impact on the cardiovascular and digestive systems - The interplay between new virus variants and human cells. Comput Struct Biotechnol J 2023;21:1022–9. [doi:10.1016/j.csbj.2023.01.024](http://dx.doi.org/10.1016/j.csbj.2023.01.024)
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=36694807&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

7.  Vosko I, Zirlik A, Bugger H. Impact of COVID-19 on cardiovascular disease. Viruses 2023;15:508. [doi:10.3390/v15020508](http://dx.doi.org/10.3390/v15020508)
    
    

8.  Huang D, Yang H, Yu H, et al. A prediction model for major adverse cardiovascular events (MACE) in patients with coronavirus disease 2019 (COVID-19). BMC Pulm Med 2022;22:343. [doi:10.1186/s12890-022-02143-3](http://dx.doi.org/10.1186/s12890-022-02143-3)
    
    

9.  Espejo-Paeres C, Núñez-Gil IJ, Estrada V, et al. Impact of smoking on COVID-19 outcomes: a HOPE Registry subanalysis. BMJ Nutr Prev Health 2021;4:285–92. [doi:10.1136/bmjnph-2021-000269](http://dx.doi.org/10.1136/bmjnph-2021-000269)
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=34308137&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

10. Kerolos MM, Ruge M, Gill A, et al. Clinical outcomes of COVID-19 infection in patients with pre-existing cardiovascular disease. Am Heart J Plus 2022;20:100189. [doi:10.1016/j.ahjo.2022.100189](http://dx.doi.org/10.1016/j.ahjo.2022.100189)
    
    

11. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. [doi:10.1016/S0140-6736(20)30183-5](http://dx.doi.org/10.1016/S0140-6736(20)30183-5)
    
    [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.1016/S0140-6736(20)30183-5&link_type=DOI) 
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

12. Guan W-J, Liang W-H, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547. [doi:10.1183/13993003.00547-2020](http://dx.doi.org/10.1183/13993003.00547-2020)
    
    

13. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020;5:802–10. [doi:10.1001/jamacardio.2020.0950](http://dx.doi.org/10.1001/jamacardio.2020.0950)
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=32211816&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

14. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62. [doi:10.1016/S0140-6736(20)30566-3](http://dx.doi.org/10.1016/S0140-6736(20)30566-3)
    
    [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.1016/S0140-6736(20)30566-3&link_type=DOI) 
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

15. Tzoulaki I, Elliott P, Kontis V, et al. Worldwide exposures to cardiovascular risk factors and associated health effects: Current knowledge and data gaps. Circulation 2016;133:2314–33. [doi:10.1161/CIRCULATIONAHA.115.008718](http://dx.doi.org/10.1161/CIRCULATIONAHA.115.008718)
    
    [Abstract/FREE Full Text](http://bmjopen.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTQ6ImNpcmN1bGF0aW9uYWhhIjtzOjU6InJlc2lkIjtzOjExOiIxMzMvMjMvMjMxNCI7czo0OiJhdG9tIjtzOjI2OiIvYm1qb3Blbi8xNC84L2UwODM5ODIuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

16. Rahman M, Shirin T, Rahman S, et al. The emergence of SARS‐CoV‐2 variants in Dhaka city, Bangladesh. Transbound Emerg Dis 2021;68:3000–1. [doi:10.1111/tbed.14203](http://dx.doi.org/10.1111/tbed.14203)
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=34170629&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

17. Afrin SZ, Islam MT, Paul SK, et al. Dynamics of SARS-CoV-2 variants of concern (VOC) in Bangladesh during the first half of 2021. Virol (Auckl) 2022;565:29–37. [doi:10.1016/j.virol.2021.10.005](http://dx.doi.org/10.1016/j.virol.2021.10.005)
    
    

18. Rahman MS, Hoque MN, Chowdhury SR, et al. Temporal dynamics and fatality of SARS-CoV-2 variants in Bangladesh. Health Sci Rep 2023;6:e1209. [doi:10.1002/hsr2.1209](http://dx.doi.org/10.1002/hsr2.1209)
    
    

19. NazmunnaharAhamed B, Haque MA, et al. COVID‐19 vaccination success in Bangladesh: Key strategies were prompt response, early drives for vaccines, and effective awareness campaigns. Health Sci Rep 2023;6:e1281. [doi:10.1002/hsr2.1281](http://dx.doi.org/10.1002/hsr2.1281)
    
    

20. Mistry SK, Ali AM, Yadav UN, et al. COVID-19 vaccination coverage is extremely low among older population in Bangladesh: findings from a cross-sectional study. Hum Vaccin Immunother 2022;18:2030624. [doi:10.1080/21645515.2022.2030624](http://dx.doi.org/10.1080/21645515.2022.2030624)
    
    

21. Chowdhury MAB, Islam M, Rahman J, et al. Changes in prevalence and risk factors of hypertension among adults in Bangladesh: An analysis of two waves of nationally representative surveys. PLoS One 2021;16:e0259507. [doi:10.1371/journal.pone.0259507](http://dx.doi.org/10.1371/journal.pone.0259507)
    
    

22. Mahmood SAI, Ali S, Islam R. Shifting from infectious diseases to non-communicable diseases: A double burden of diseases in Bangladesh. J Public Health Epidemiol 2013;5:424–34.
    
    

23. Khanam F, Hossain MB, Mistry SK, et al. Prevalence and risk factors of cardiovascular diseases among Bangladeshi adults: findings from a cross-sectional study. J Epidemiol Glob Health 2019;9:176–84. [doi:10.2991/jegh.k.190531.001](http://dx.doi.org/10.2991/jegh.k.190531.001)
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=31529935&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

24. Sliwa K, Singh K, Raspail L, et al. The World Heart Federation Global Study on COVID-19 and Cardiovascular Disease. Glob Heart 2021;16:22. [doi:10.5334/gh.950](http://dx.doi.org/10.5334/gh.950)
    
    

25. Prabhakaran D, Singh K, Kondal D, et al. Cardiovascular risk factors and clinical outcomes among patients hospitalized with COVID-19: Findings from the world heart federation COVID-19 study. Glob Heart 2022;17:40. [doi:10.5334/gh.1128](http://dx.doi.org/10.5334/gh.1128)
    
    

26. Bosco E, Hsueh L, McConeghy KW, et al. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol 2021;21:241. [doi:10.1186/s12874-021-01440-5](http://dx.doi.org/10.1186/s12874-021-01440-5)
    
    

27. Wiscovitch-Russo R, Ibáñez-Prada ED, Serrano-Mayorga CC, et al. Major adverse cardiovascular events are associated with necroptosis during severe COVID-19. Crit Care 2023;27:155. [doi:10.1186/s13054-023-04423-8](http://dx.doi.org/10.1186/s13054-023-04423-8)
    
    

28. Joseph P, Kutty VR, Mohan V, et al. Cardiovascular disease, mortality, and their associations with modifiable risk factors in a multi-national South Asia cohort: a PURE substudy. Eur Heart J 2022;43:2831–40. [doi:10.1093/eurheartj/ehac249](http://dx.doi.org/10.1093/eurheartj/ehac249)
    
    [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.1093/eurheartj/ehac249&link_type=DOI) 
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=35731159&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

29. Pellicori P, Doolub G, Wong CM, et al. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database Syst Rev 2021;3:CD013879. [doi:10.1002/14651858.CD013879](http://dx.doi.org/10.1002/14651858.CD013879)
    
    

30. Nandy K, Salunke A, Pathak SK, et al. Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events. Diabetes Metab Syndr 2020;14:1017–25. [doi:10.1016/j.dsx.2020.06.064](http://dx.doi.org/10.1016/j.dsx.2020.06.064)
    
    [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.1016/j.dsx.2020.06.064&link_type=DOI) 
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=32634716&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

31. Szarpak L, Mierzejewska M, Jurek J, et al. Effect of coronary artery disease on COVID-19-prognosis and risk assessment: A systematic review and meta-analysis. Biol (Basel) 2022;11:221. [doi:10.3390/biology11020221](http://dx.doi.org/10.3390/biology11020221)
    
    

32. Cabezón Villalba G, Amat-Santos IJ, Dueñas C, et al. Impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in COVID-19. Cardiol J 2021;28:360–8. [doi:10.5603/CJ.a2021.0034](http://dx.doi.org/10.5603/CJ.a2021.0034)
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=33843043&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

33. Pya Y, Bekbossynova M, Gaipov A, et al. Mortality predictors of hospitalized patients with COVID-19: Retrospective cohort study from Nur-Sultan, Kazakhstan. PLoS One 2021;16:e0261272. [doi:10.1371/journal.pone.0261272](http://dx.doi.org/10.1371/journal.pone.0261272)
    
    

34. Adjei S, Hong K, Molinari N-AM, et al. Mortality risk among patients hospitalized primarily for COVID-19 during the omicron and delta variant pandemic periods — United States, April 2020–June 2022. MMWR Morb Mortal Wkly Rep 2022;71:1182–9. [doi:10.15585/mmwr.mm7137a4](http://dx.doi.org/10.15585/mmwr.mm7137a4)
    
    [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.15585/mmwr.mm7137a4&link_type=DOI) 
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=36107788&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

35. Ikram AS, Pillay S. Admission vital signs as predictors of COVID-19 mortality: a retrospective cross-sectional study. BMC Emerg Med 2022;22:68. [doi:10.1186/s12873-022-00631-7](http://dx.doi.org/10.1186/s12873-022-00631-7)
    
    

36. Yoshida Y, Gillet SA, Brown MI, et al. Clinical characteristics and outcomes in women and men hospitalized for coronavirus disease 2019 in New Orleans. Biol Sex Differ 2021;12:20. [doi:10.1186/s13293-021-00359-2](http://dx.doi.org/10.1186/s13293-021-00359-2)
    
    

37. Xiang G, Xie L, Chen Z, et al. Clinical risk factors for mortality of hospitalized patients with COVID-19: systematic review and meta-analysis. Ann Palliat Med 2021;10:2723–35. [doi:10.21037/apm-20-1278](http://dx.doi.org/10.21037/apm-20-1278)
    
    [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.21037/apm-20-1278&link_type=DOI) 
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=33549005&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

38. Cortez KJC, Demot BA, Bartolo SS, et al. Clinical characteristics and outcomes of COVID-19 patients in a tertiary hospital in Baguio City, Philippines. Western Pac Surveill Response J 2021;12:1–11. [doi:10.5365/wpsar.2021.12.4.852](http://dx.doi.org/10.5365/wpsar.2021.12.4.852)
    
    

39. Hernandez-Hernandez ME, Zee RYL, Pulido-Perez P, et al. The effects of biological sex and cardiovascular disease on COVID-19 mortality. Am J Physiol Heart Circ Physiol 2022;323:H397–402. [doi:10.1152/ajpheart.00295.2022](http://dx.doi.org/10.1152/ajpheart.00295.2022)
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=35867708&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

40. Pandita A, Gillani FS, Shi Y, et al. Predictors of severity and mortality among patients hospitalized with COVID-19 in Rhode Island. PLoS One 2021;16:e0252411. [doi:10.1371/journal.pone.0252411](http://dx.doi.org/10.1371/journal.pone.0252411)
    
    

41. Hall EJ, Ayers CR, Kolkailah AA, et al. Longitudinal trends in cardiovascular risk factor profiles and complications among patients hospitalized for COVID-19 infection: Results from the American Heart Association COVID-19 cardiovascular disease registry. Circ Cardiovasc Qual Outcomes 2023;16:e009652. [doi:10.1161/CIRCOUTCOMES.122.009652](http://dx.doi.org/10.1161/CIRCOUTCOMES.122.009652)
    
    

42. Tolu-Akinnawo O, Adusei Poku F, Elimihele T, et al. Acute cardiovascular complications of COVID-19: A systematic review. Cureus 2023;15:e38576. [doi:10.7759/cureus.38576](http://dx.doi.org/10.7759/cureus.38576)
    
    

43. Fortuna D, Caselli L, Berti E, et al. Direct impact of 2 years of COVID-19 on chronic disease patients: a population-based study in a large hard-hit Italian region. BMJ Open 2023;13:e073471. [doi:10.1136/bmjopen-2023-073471](http://dx.doi.org/10.1136/bmjopen-2023-073471)
    
    

44. Karageorgou V, Papaioannou AI, Kallieri M, et al. Patients hospitalized for COVID-19 in the periods of delta and omicron variant dominance in Greece: Determinants of severity and mortality. J Clin Med 2023;12:5904. [doi:10.3390/jcm12185904](http://dx.doi.org/10.3390/jcm12185904)
    
    

45. Araújo CR da S, Fernandes J, Caetano DS, et al. Endothelial function, arterial stiffness and heart rate variability of patients with cardiovascular diseases hospitalized due to COVID-19. H L 2023;58:210–6. [doi:10.1016/j.hrtlng.2022.12.016](http://dx.doi.org/10.1016/j.hrtlng.2022.12.016)
    
    

46. Liu T-H, Chuang M-H, Wu J-Y, et al. Effectiveness of oral antiviral agents on long-term cardiovascular risk in nonhospitalized patients with COVID-19: A multicenter matched cohort study. J Med Virol 2023;95:e28992. [doi:10.1002/jmv.28992](http://dx.doi.org/10.1002/jmv.28992)
    
    

47. Yao Q, Ni J, Hu T-T, et al. Clinical characteristics and outcomes in coronavirus disease 2019 (COVID-19) patients with and without hypertension: a retrospective study. Rev Cardiovasc Med 2020;21:615–25. [doi:10.31083/j.rcm.2020.04.113](http://dx.doi.org/10.31083/j.rcm.2020.04.113)
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

48. Kamarullah W, NurcahyaniMary Josephine C, et al. Corticosteroid therapy in management of myocarditis associated with COVID-19; a systematic review of current evidence. Arch Acad Emerg Med 2021;9:e32. [doi:10.22037/aaem.v9i1.1153](http://dx.doi.org/10.22037/aaem.v9i1.1153)
    
    

49. Hoertel N, Sánchez-Rico M, Vernet R, et al. Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study. Br J Clin Pharmacol 2021;87:3766–75. [doi:10.1111/bcp.14784](http://dx.doi.org/10.1111/bcp.14784)
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=33608891&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

50. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384:693–704. [doi:10.1056/NEJMoa2021436](http://dx.doi.org/10.1056/NEJMoa2021436)
    
    [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.1056/NEJMoa2021436&link_type=DOI) 
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

51. Asaduzzaman M, Nazmul Alam ZHM, Zabed Jillul Bari M, et al. Clinical characteristics and predictors of mortality in elderly patients hospitalized with COVID-19 in Bangladesh: A multicenter, retrospective study. Interdiscip Perspect Infect Dis 2022;2022:5904332. [doi:10.1155/2022/5904332](http://dx.doi.org/10.1155/2022/5904332)
    
    

52. Liao CT, Chang WT, Yu WL, et al. Management of acutecardiovascularevents in patients with COVID-19. Rev Cardiovasc Med 2020;21:577–81. [doi:10.31083/j.rcm.2020.04.140](http://dx.doi.org/10.31083/j.rcm.2020.04.140)
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=33388002&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom) 

53. Cezard GI, Denholm RE, Knight R, et al. Impact of vaccination on the association of COVID-19 with cardiovascular diseases: An OpenSAFELY cohort study. Nat Commun 2024;15:2173. [doi:10.1038/s41467-024-46497-0](http://dx.doi.org/10.1038/s41467-024-46497-0)
    
    

54. Akhtar Z, Trent M, Moa A, et al. The impact of COVID-19 and COVID vaccination on cardiovascular outcomes. Eur Heart J Suppl 2023;25:A42–9. [doi:10.1093/eurheartjsupp/suac123](http://dx.doi.org/10.1093/eurheartjsupp/suac123)
    
    [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=36937372&link_type=MED&atom=%2Fbmjopen%2F14%2F8%2Fe083982.atom)